Literature DB >> 26850074

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.

J Bradford Rice1, Alan White1, Andrea Lopez1, Philip Galebach1, Patricia Schepman2, Breanna Popelar3, Michael Philbin2.   

Abstract

Background Dermatomyositis and polymyositis (DM/PM) are inflammatory myopathies characterized by muscle inflammation/weakness. Patients with DM/PM have a reduced quality-of-life and are at an increased risk for several comorbidities. Studies have assessed the incidence and prevalence of DM/PM; however, no study has estimated the burden of the diseases in terms of both healthcare resource utilization (HCRU) and work loss incurred by patients. Objective To provide a comprehensive, current estimate of the annual HCRU and work loss in DM/PM patients in the US. Methods All patients (aged 18-64 years) with a first diagnosis of DM/PM between January 1, 1998 and March 31, 2014 ('index date') were selected from a de-identified privately-insured administrative claims database. DM/PM patients were required to have continuous health-plan enrollment 12 months prior to and following their index date. Propensity-score (1:1) matching of DM/PM patients with non-DM/PM controls was carried out based on a logistic regression of demographic characteristics, comorbidities, costs, and HCRU to control for these confounding factors. Burden of HCRU and work loss (disability days and medically-related absenteeism) were compared between the matched DM/PM and the non-DM/PM cohorts over the 12-month period after the index date ('outcome period'). Results Of the 2617 DM/PM patients that met sample selection criteria, 2587 (98.9%) were matched with a non-DM/PM control. During the outcome period, DM/PM patients had significantly increased HCRU across places of service, including 44% more inpatient admissions (3.6 vs 2.5, p < 0.001), increased visits with specialists such as rheumatologists, neurologists and physical therapists, and filled 4.7 more prescriptions (32.2 vs 27.5, p < 0.001) than matched control patients. The increased HCRU led to significantly more medically-related work loss among DM/PM patients than matched controls (p < 0.001). Conclusions DM/PM imposes a substantial increase in healthcare resource use and is associated with statistically significantly greater work loss in the first year following diagnosis.

Entities:  

Keywords:  Dermatomyositis; burden; payer burden; polymyositis

Mesh:

Year:  2016        PMID: 26850074     DOI: 10.3111/13696998.2016.1151433

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  4 in total

Review 1.  Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases.

Authors:  Natalie McCormick; Carlo A Marra; J Antonio Aviña-Zubieta
Journal:  Curr Rheumatol Rep       Date:  2017-10-30       Impact factor: 4.592

2.  High-Dimensional Analysis Reveals Distinct Endotypes in Patients With Idiopathic Inflammatory Myopathies.

Authors:  Erin M Wilfong; Todd Bartkowiak; Katherine N Vowell; Camille S Westlake; Jonathan M Irish; Peggy L Kendall; Leslie J Crofford; Rachel H Bonami
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 8.786

3.  Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab.

Authors:  Tyler Knight; T Christopher Bond; Breanna Popelar; Li Wang; John W Niewoehner; Kathryn Anastassopoulos; Michael Philbin
Journal:  Clinicoecon Outcomes Res       Date:  2017-05-16

4.  Clinical and economic burden of prescribing tramadol and other opioids for patients with osteoarthritis in a commercially insured population in the United States.

Authors:  Stuart Silverman; J Bradford Rice; Alan G White; Craig G Beck; Rebecca L Robinson; Catherine Fernan; Patricia Schepman
Journal:  Pain       Date:  2022-01-01       Impact factor: 6.961

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.